Free Float 69,70 %
Shares Float 32,09 M
Shares Outstanding 46,05 M
Helixmith Co., Ltd Share · KR7084990001 (XKOS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Helixmith Co., Ltd
No Price
Closing Price XKOS 30.04.2026:
8.620,00 KRW
30.04.2026 06:30
Current Prices from Helixmith Co., Ltd
| Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
|---|---|---|---|---|---|
 KOSDAQ |
084990.KQ
|
KRW
|
30.04.2026 06:30
|
8.620,00 KRW
| - |
Share Float & Liquidity
Invested Funds
The following funds have invested in Helixmith Co., Ltd:
Fund | Vol. in million 92,34 | Percentage (%) 0,09 % |
Fund | Vol. in million 34,72 | Percentage (%) 0,01 % |
Fund | Vol. in million 175,79 | Percentage (%) 0,01 % |
Company Profile for Helixmith Co., Ltd Share
Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological diseases. The company's pipeline products include VM206, a therapeutic cancer vaccine targeting HER2/neu positive breast or ovarian cancer; and VM501, a re-engineered form of interleukin 11 targeting chemotherapy-induced thrombocytopenia. Its clinical trials biologics comprise VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. The company was formerly known as ViroMed Co., Ltd. and changed its name to Helixmith Co., Ltd in April 2019. Helixmith Co., Ltd was incorporated in 1996 and is headquartered in Seoul, South Korea.
Company Data
Name Helixmith Co., Ltd
Company Helixmith Co., Ltd
Website
https://www.helixmith.com
Primary Exchange
KOSDAQ
KOSDAQ
ISIN KR7084990001
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Sunyoung Kim D.Phil.,
Market Capitalization 397 Mrd.
Country South Korea
Currency KRW
Employees 0,1 T
Address Building 203, 151-747 Seoul
IPO Date 2005-12-29
Dividends from 'Helixmith Co., Ltd'
| Ex-Date | Dividend per Share |
|---|---|
| 15.03.2022 | 0,29 KRW |
Stock Splits
| Date | Split |
|---|---|
| 29.12.2021 | 11:10 |
| 13.11.2020 | 213:200 |
| 22.04.2020 | 25:22 |
| 13.08.2019 | 10:11 |
| 28.06.2019 | 509:500 |
| 05.09.2016 | 517:500 |
Ticker Symbols
| Name | Symbol |
|---|---|
| KOSDAQ | 084990.KQ |
More Shares
Investors who hold Helixmith Co., Ltd also have the following shares in their portfolio:
